Theravance Biopharma Reaffirms Financial Guidance Amid Trial Failure
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Mar 18 2026
0mins
Should l Buy TBPH?
Source: Newsfilter
- Stock Price Collapse: Theravance Biopharma's shares plummeted approximately 26% on March 3, 2026, reflecting a strong market reaction to the failure of its CYPRESS Phase 3 trial, which severely undermined investor confidence.
- Reaffirmed Financial Guidance: In the quarters leading up to the drop, management reaffirmed financial guidance, including $75 million in near-term milestone targets, without quantifying the potential risks of a CYPRESS trial failure, which may lead to diminished investor trust in the company's future.
- Accelerated Strategic Review: Following the CYPRESS trial's failure to meet its primary endpoint, Theravance announced an accelerated strategic review and the termination of the ampreloxetine program, a decision that could incur restructuring costs and necessitate a fundamental reassessment of development-stage spending, further impacting the company's financial outlook.
- Investor Losses: The lack of adequate disclosure regarding the risks associated with the CYPRESS trial has left many investors facing losses, significantly increasing the demand for legal consultation and claims, which may lead to subsequent litigation.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy TBPH?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on TBPH
Wall Street analysts forecast TBPH stock price to rise
5 Analyst Rating
4 Buy
1 Hold
0 Sell
Strong Buy
Current: 17.020
Low
13.00
Averages
28.40
High
42.00
Current: 17.020
Low
13.00
Averages
28.40
High
42.00
About TBPH
Theravance Biopharma, Inc. is a biopharmaceutical company primarily focused on the development and commercialization of medicines for the specialty respiratory and neurologic diseases. The Company operates through a single segment, namely, development and commercialization of human therapeutics. Its product, YUPELRI (revefenacin) inhalation solution, is a nebulized long-acting muscarinic antagonist used for the treatment of patients with chronic obstructive pulmonary disease (COPD). COPD is a long-term lung disease that includes chronic bronchitis, emphysema, or both. YUPELRI is an anticholinergic medicine, which helps the muscles around the airway in the lungs stay relaxed to prevent symptoms, such as wheezing, shortness of breath, and others. Its Ampreloxetine, is a late-stage investigational norepinephrine reuptake inhibitor in development for the treatment of symptomatic neurogenic orthostatic hypotension in patients with Multiple System Atrophy.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Theravance Biopharma Under Investigation for Securities Fraud Claims
- Securities Fraud Investigation: Pomerantz LLP is investigating claims against Theravance Biopharma, Inc. regarding potential securities fraud and unlawful business practices by the company and its executives, which could lead to significant investor losses.
- Clinical Trial Failure: On March 3, 2026, Theravance announced that its Phase 3 CYPRESS study for ampreloxetine, aimed at treating neurogenic orthostatic hypotension, failed to meet its primary endpoint, prompting the company to wind down the program and negatively impacting investor confidence.
- Significant Stock Drop: Following the disappointing clinical trial results, Theravance's stock price plummeted by $4.99, or 26.33%, closing at $13.96 per share on March 3, 2026, indicating market concerns regarding the company's future prospects.
- Legal Firm Involvement: Pomerantz LLP, a prominent firm in securities class action litigation, has been advocating for investor rights for over 85 years and is currently offering legal support to affected investors, which may lead to further legal actions.
See More
Theravance Biopharma Q1 Earnings Analysis
- Earnings Report: Theravance Biopharma reported a Q1 GAAP EPS of -$0.10, missing expectations by $0.13, indicating challenges in profitability that could impact investor confidence.
- Revenue Growth: The company achieved Q1 revenue of $17.7 million, a 14.9% year-over-year increase, beating market expectations by $0.25 million, suggesting sustained demand for its products and laying a foundation for future business expansion.
- Drug Development Setback: Theravance dropped a rare disease drug after a late-stage trial failure, reflecting significant risks in its R&D pipeline that could negatively affect future revenue sources.
- Investment Moves: Summers Value Fund increased its stake in TBPH while exiting ADMA in Q1, indicating growing confidence in Theravance, which may attract other investors looking at its potential 50-100% upside.
See More
Theravance Biopharma Reports Strong Q1 2026 Financial Results and Strategic Restructuring
- Strong Financial Performance: Theravance Biopharma reported Q1 2026 net sales of $17.7 million, a 15% increase year-over-year, demonstrating the quality of its commercial assets and sustained profitability, particularly with growing adoption of YUPELRI®.
- Implementation of Restructuring Plan: The company is undergoing an organizational restructuring expected to reduce operating expenses by approximately 60% from $111.1 million in 2025, with projected annual cash flow of $70 million by Q3 2026, enhancing financial flexibility.
- Formation of Strategic Review Committee: The Board established a Strategic Review Committee to evaluate various strategic alternatives, including a potential sale of the company, reflecting a strong commitment to maximizing shareholder value and future growth.
- Optimistic Market Outlook: TRELEGY's global net sales reached $873 million in Q1 2026, with a milestone payment of $100 million anticipated, further solidifying the company's position in the respiratory drug market.
See More
THERAVANCE BIOPHARMA INC ANTICIPATES AROUND 60% DECREASE IN OPERATING EXPENSES DUE TO RESTRUCTURING
Restructuring Announcement: The company, RAVANCE BIOPHARMA, is expected to undergo restructuring.
Cost Reduction Goals: This restructuring aims to reduce operating expenses by approximately 60%.
See More
Theravance Biopharma Under Investigation for Securities Fraud Claims
- Securities Fraud Investigation: Pomerantz LLP is investigating claims against Theravance Biopharma, Inc. regarding potential securities fraud by the company and its executives, which could lead to significant losses for investors.
- Clinical Trial Failure: On March 3, 2026, Theravance announced that its Phase 3 CYPRESS study for ampreloxetine in patients with multiple system atrophy (MSA) failed to meet its primary endpoint, prompting the company to wind down the program, which could impact its future product pipeline.
- Significant Stock Drop: Following the disappointing clinical trial results, Theravance's stock price plummeted by $4.99, or 26.33%, closing at $13.96 per share on March 3, 2026, indicating a negative market sentiment towards the company's future prospects.
- Investor Advisory: Pomerantz LLP advises investors who may have suffered losses during this period to contact the firm for information on joining the class action, highlighting the importance of protecting investor rights.
See More
Summers Value Fund LP Reports -2.7% Return in Q1 2026, Underperforming Indices
- Fund Performance Review: The Summers Value Fund LP reported a net return of -2.7% in Q1 2026, significantly underperforming the Russell 2000 Index ETF's 0.9% and the Russell 2000 Value Index ETF's 4.9%, indicating challenges in small-cap investments.
- Key Contributors and Detractors: Major contributors to the fund's performance included Liquidia (LQDA), Avanos Medical (AVNS), and Consensus Cloud Solutions (CCSI), while Electromed (ELMD) and Embecta (EMBC) were the largest detractors, highlighting the portfolio's volatility.
- Investment Strategy Adjustments: The fund initiated a new position in Theravance (TBPH) and exited ADMA Biologics (ADMA) due to the latter's failure to meet expectations, indicating the fund's focus on identifying more attractive investment opportunities.
- Position Strengthening: The fund strengthened its position in Embecta (EMBC) following a sell-off after the company narrowed its fiscal 2026 guidance to the low end of the range, demonstrating the fund's confidence in the stock and its strategic response to market fluctuations.
See More
Theravance Biopharma Under Investigation for Securities Fraud Claims
- Securities Fraud Investigation: Pomerantz LLP is investigating claims against Theravance Biopharma, Inc. regarding potential securities fraud and unlawful business practices by the company and its executives, which could lead to significant investor losses.
- Clinical Trial Failure: On March 3, 2026, Theravance announced that its Phase 3 CYPRESS study for ampreloxetine, aimed at treating neurogenic orthostatic hypotension, failed to meet its primary endpoint, prompting the company to wind down the program and negatively impacting investor confidence.
- Significant Stock Drop: Following the disappointing clinical trial results, Theravance's stock price plummeted by $4.99, or 26.33%, closing at $13.96 per share on March 3, 2026, indicating market concerns regarding the company's future prospects.
- Legal Firm Involvement: Pomerantz LLP, a prominent firm in securities class action litigation, has been advocating for investor rights for over 85 years and is currently offering legal support to affected investors, which may lead to further legal actions.
See More
Theravance Biopharma Q1 Earnings Analysis
- Earnings Report: Theravance Biopharma reported a Q1 GAAP EPS of -$0.10, missing expectations by $0.13, indicating challenges in profitability that could impact investor confidence.
- Revenue Growth: The company achieved Q1 revenue of $17.7 million, a 14.9% year-over-year increase, beating market expectations by $0.25 million, suggesting sustained demand for its products and laying a foundation for future business expansion.
- Drug Development Setback: Theravance dropped a rare disease drug after a late-stage trial failure, reflecting significant risks in its R&D pipeline that could negatively affect future revenue sources.
- Investment Moves: Summers Value Fund increased its stake in TBPH while exiting ADMA in Q1, indicating growing confidence in Theravance, which may attract other investors looking at its potential 50-100% upside.
See More
Theravance Biopharma Reports Strong Q1 2026 Financial Results and Strategic Restructuring
- Strong Financial Performance: Theravance Biopharma reported Q1 2026 net sales of $17.7 million, a 15% increase year-over-year, demonstrating the quality of its commercial assets and sustained profitability, particularly with growing adoption of YUPELRI®.
- Implementation of Restructuring Plan: The company is undergoing an organizational restructuring expected to reduce operating expenses by approximately 60% from $111.1 million in 2025, with projected annual cash flow of $70 million by Q3 2026, enhancing financial flexibility.
- Formation of Strategic Review Committee: The Board established a Strategic Review Committee to evaluate various strategic alternatives, including a potential sale of the company, reflecting a strong commitment to maximizing shareholder value and future growth.
- Optimistic Market Outlook: TRELEGY's global net sales reached $873 million in Q1 2026, with a milestone payment of $100 million anticipated, further solidifying the company's position in the respiratory drug market.
See More
THERAVANCE BIOPHARMA INC ANTICIPATES AROUND 60% DECREASE IN OPERATING EXPENSES DUE TO RESTRUCTURING
Restructuring Announcement: The company, RAVANCE BIOPHARMA, is expected to undergo restructuring.
Cost Reduction Goals: This restructuring aims to reduce operating expenses by approximately 60%.
See More
Theravance Biopharma Under Investigation for Securities Fraud Claims
- Securities Fraud Investigation: Pomerantz LLP is investigating claims against Theravance Biopharma, Inc. regarding potential securities fraud by the company and its executives, which could lead to significant losses for investors.
- Clinical Trial Failure: On March 3, 2026, Theravance announced that its Phase 3 CYPRESS study for ampreloxetine in patients with multiple system atrophy (MSA) failed to meet its primary endpoint, prompting the company to wind down the program, which could impact its future product pipeline.
- Significant Stock Drop: Following the disappointing clinical trial results, Theravance's stock price plummeted by $4.99, or 26.33%, closing at $13.96 per share on March 3, 2026, indicating a negative market sentiment towards the company's future prospects.
- Investor Advisory: Pomerantz LLP advises investors who may have suffered losses during this period to contact the firm for information on joining the class action, highlighting the importance of protecting investor rights.
See More
Summers Value Fund LP Reports -2.7% Return in Q1 2026, Underperforming Indices
- Fund Performance Review: The Summers Value Fund LP reported a net return of -2.7% in Q1 2026, significantly underperforming the Russell 2000 Index ETF's 0.9% and the Russell 2000 Value Index ETF's 4.9%, indicating challenges in small-cap investments.
- Key Contributors and Detractors: Major contributors to the fund's performance included Liquidia (LQDA), Avanos Medical (AVNS), and Consensus Cloud Solutions (CCSI), while Electromed (ELMD) and Embecta (EMBC) were the largest detractors, highlighting the portfolio's volatility.
- Investment Strategy Adjustments: The fund initiated a new position in Theravance (TBPH) and exited ADMA Biologics (ADMA) due to the latter's failure to meet expectations, indicating the fund's focus on identifying more attractive investment opportunities.
- Position Strengthening: The fund strengthened its position in Embecta (EMBC) following a sell-off after the company narrowed its fiscal 2026 guidance to the low end of the range, demonstrating the fund's confidence in the stock and its strategic response to market fluctuations.
See More
